Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5254382 | 0.80 | KCNH2 (0.51) | KCNH2SLC2A1 | |
| SCHEMBL1267923 | 0.73 | KCNH2 (0.46) | KCNH2SLC2A1 | |
| SCHEMBL3687654 | 0.73 | KCNH2 (0.37) | KCNH2 | |
| SCHEMBL1076723 | 0.72 | KCNH2 (0.41) | KCNH2SLC2A1 | |
| SCHEMBL622101 | 0.72 | KCNH2 (0.35) | KCNH2SLC2A1 | |
| SCHEMBL2540548 | 0.72 | KCNH2 (0.37) | KCNH2SLC2A1 | |
| SCHEMBL2539639 | 0.72 | KCNH2 (0.37) | KCNH2SLC2A1 | |
| SCHEMBL5432611 | 0.72 | KCNH2 (0.33) | KCNH2 | |
| SCHEMBL5508377 | 0.71 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL5433395 | 0.71 | KCNH2 (0.33) | KCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | claimed |
| US-8012961-B2 | Tricyclic antibiotics | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-09-06 | — | — | US | disclosed |
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | OPRM1, UBE2D3, METTL3 | KCNH2 924/4885SLC2A1 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.